{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:54:59Z","timestamp":1793318099848,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Oropharyngeal carcinomas are characterized by an increasing incidence and a relatively good prognosis. Nonetheless, a considerable number of patients develops metachronous distant metastases; identification of these patients is an urgent medical need.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This is a retrospective multicenter evaluation of 431 patients. All patients underwent [<jats:sup>18<\/jats:sup>F]-FDG positron emission tomography (PET). The cohort was split into an explorative group (<jats:italic>n<\/jats:italic>\u2009=\u2009366) and a validation group (<jats:italic>n<\/jats:italic>\u2009=\u200965). Lesions were manually delineated in the explorative group and automatically delineated by a convolutional neuronal network (CNN) in the validation group. Quantitative PET parameters standardized uptake value (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were calculated for primary tumors (<jats:sub>prim<\/jats:sub>) and tumor plus lymphnodes (<jats:sub>all<\/jats:sub>). Association of parameters with freedom from distant metastases (FFDM) and overall survival (OS) was tested by cox regression analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In the explorative group, univariate analyses revealed an association of metric MTV<jats:sub>prim<\/jats:sub> (<jats:italic>p<\/jats:italic>\u2009=\u20090.022), MTV<jats:sub>all<\/jats:sub> (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and TLG<jats:sub>all<\/jats:sub> (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) with FFDM, binarized parameters were also associated with FFDM (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 and <jats:italic>p<\/jats:italic>\u2009=\u20090.002). Bootstrap analyses revealed a significantly better association of TLG<jats:sub>all<\/jats:sub> compared to TLG<jats:sub>prim<\/jats:sub> with FFDM (<jats:italic>p<\/jats:italic>\u2009=\u20090.02). MTV<jats:sub>all<\/jats:sub> and TLG<jats:sub>all<\/jats:sub> remained significantly associated with FFDM upon multivariate testing (<jats:italic>p<\/jats:italic>\u2009=\u20090.002, <jats:italic>p<\/jats:italic>\u2009=\u20090.031, respectively). In the validation group, the cutoff value for TLG<jats:sub>all<\/jats:sub> but not for TLG<jats:sub>prim<\/jats:sub> was significantly associated with FFDM (HR\u2009=\u20093.1, <jats:italic>p<\/jats:italic>\u2009=\u20090.045). Additional analyses with manually delineated contours of the validation cohort revealed a similar effect (HR\u2009=\u20093.47, <jats:italic>p<\/jats:italic>\u2009=\u20090.026). No considerable differences between HPV positive and negative disease were observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>TLG<jats:sub>all<\/jats:sub> is a promising biomarker to select OPC patients with high risk for metachronous distant metastases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40644-025-00836-6","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:31:09Z","timestamp":1740137469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Total lesion glycolysis of primary tumor and lymphnodes is a strong predictor for development of distant metastases in oropharyngeal carcinoma patients with independent validation in automatically delineated lesions"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3109-0662","authenticated-orcid":false,"given":"Sebastian","family":"Zschaeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Hajiyianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hausmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Nikulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Kukuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Furth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Cegla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kazmierska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iosif","family":"Strouthos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Stromberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mechthild","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Landry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witold","family":"Cholewinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"Kotzerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"van den Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hofheinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"836_CR1","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1200\/JCO.2013.50.3870","volume":"31","author":"AK Chaturvedi","year":"2013","unstructured":"Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol off J Am Soc Clin Oncol. 2013;31:4550\u20139.","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"836_CR2","first-page":"308","volume":"157","author":"T Dyba","year":"2021","unstructured":"Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, et al. The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer Oxf Engl 1990. 2021;157:308\u201347.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"836_CR3","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1158\/1055-9965.EPI-19-0038","volume":"28","author":"BA Mahal","year":"2019","unstructured":"Mahal BA, Catalano PJ, Haddad RI, Hanna GJ, Kass JI, Schoenfeld JD, et al. Incidence and demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2019;28:1660\u20137.","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"key":"836_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-T\u00e2n PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24\u201335.","journal-title":"N Engl J Med"},{"key":"836_CR5","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1200\/JCO.21.01961","volume":"40","author":"AC Nichols","year":"2022","unstructured":"Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Randomized Trial of Radiotherapy Versus Transoral robotic surgery for Oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. J Clin Oncol off J Am Soc Clin Oncol. 2022;40:866\u201375.","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"836_CR6","doi-asserted-by":"publisher","first-page":"e2428526","DOI":"10.1001\/jamanetworkopen.2024.28526","volume":"7","author":"L Sun","year":"2024","unstructured":"Sun L, Cohen RB, D\u2019Avella CA, Singh AP, Schoenfeld JD, Hanna GJ. Overall survival, treatment duration, and rechallenge outcomes with ICI therapy for recurrent or metastatic HNSCC. JAMA Netw Open. 2024;7:e2428526.","journal-title":"JAMA Netw Open"},{"key":"836_CR7","doi-asserted-by":"publisher","first-page":"S1310","DOI":"10.1016\/j.annonc.2021.08.2112","volume":"32","author":"J Bourhis","year":"2021","unstructured":"Bourhis J, Tao Y, Sun X, Sire C, Martin L, Liem X, et al. LBA35 avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): randomized phase III GORTEC-REACH trial. Ann Oncol. 2021;32:S1310.","journal-title":"Ann Oncol"},{"key":"836_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","volume":"22","author":"NY Lee","year":"2021","unstructured":"Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22:450\u201362.","journal-title":"Lancet Oncol"},{"key":"836_CR9","doi-asserted-by":"crossref","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al. Overall survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018.","DOI":"10.1056\/NEJMoa1809697"},{"key":"836_CR10","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1056\/NEJMoa1514493","volume":"374","author":"H Mehanna","year":"2016","unstructured":"Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M, Hartley AGJ, et al. PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. N Engl J Med. 2016;374:1444\u201354.","journal-title":"N Engl J Med"},{"key":"836_CR11","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1007\/s00259-023-06197-1","volume":"50","author":"P Nikulin","year":"2023","unstructured":"Nikulin P, Zschaeck S, Maus J, Cegla P, Lombardo E, Furth C, et al. A convolutional neural network with self-attention for fully automated metabolic tumor volume delineation of head and neck cancer in [Formula: see text]F]FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2023;50:2751\u201366.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"836_CR12","unstructured":"Beichel RR, Ulrich EJ, Bauer C, Wahle A, Brown B, Chang T et al. Data From QIN-HEADNECK. 2015 [cited 2020 Jun 10]; Available from: https:\/\/wiki.cancerimagingarchive.net\/x\/qQ9p"},{"key":"836_CR13","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s10278-013-9622-7","volume":"26","author":"K Clark","year":"2013","unstructured":"Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, et al. The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J Digit Imaging. 2013;26:1045\u201357.","journal-title":"J Digit Imaging"},{"key":"836_CR14","doi-asserted-by":"publisher","first-page":"180173","DOI":"10.1038\/sdata.2018.173","volume":"5","author":"AJ Grossberg","year":"2018","unstructured":"Grossberg AJ, Mohamed ASR, Elhalawani H, Bennett WC, Smith KE, Nolan TS, et al. Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Sci Data. 2018;5:180173.","journal-title":"Sci Data"},{"key":"836_CR15","unstructured":"Valli\u00e8res M, Kay-Rivest E, Perrin L, Liem X, Furstoss C, Khaouam N et al. Data from Head-Neck-PET-CT [Internet]. The Cancer Imaging Archive; 2017 [cited 2020 Jun 10]. Available from: https:\/\/wiki.cancerimagingarchive.net\/x\/24pyAQ"},{"key":"836_CR16","unstructured":"Wee L, Dekker A. Data from Head-Neck-Radiomics-HN1 [Internet]. The Cancer Imaging Archive; 2019 [cited 2020 Oct 13]. Available from: https:\/\/wiki.cancerimagingarchive.net\/x\/iBglAw"},{"key":"836_CR17","unstructured":"Zuley ML, Jarosz R, Kirk S, Lee Y, Colen R, Garcia K et al. Radiology Data from The Cancer Genome Atlas Head-Neck Squamous Cell Carcinoma [TCGA-HNSC] collection [Internet]. The Cancer Imaging Archive; 2016 [cited 2020 Oct 13]. Available from: https:\/\/wiki.cancerimagingarchive.net\/x\/VYG0"},{"key":"836_CR18","doi-asserted-by":"publisher","first-page":"870319","DOI":"10.3389\/fonc.2022.870319","volume":"12","author":"S Zschaeck","year":"2022","unstructured":"Zschaeck S, Weing\u00e4rtner J, Lombardo E, Marschner S, Hajiyianni M, Beck M, et al. 18F-Fluorodeoxyglucose Positron Emission Tomography of Head and Neck Cancer: location and HPV specific parameters for potential treatment individualization. Front Oncol. 2022;12:870319.","journal-title":"Front Oncol"},{"key":"836_CR19","doi-asserted-by":"publisher","first-page":"082503","DOI":"10.1118\/1.4812892","volume":"40","author":"F Hofheinz","year":"2013","unstructured":"Hofheinz F, Langner J, Petr J, Beuthien-Baumann B, Steinbach J, Kotzerke J, et al. An automatic method for accurate volume delineation of heterogeneous tumors in PET. Med Phys. 2013;40:082503.","journal-title":"Med Phys"},{"key":"836_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-00034924","volume":"51","author":"F Hofheinz","year":"2012","unstructured":"Hofheinz F, P\u00f6tzsch C, Oehme L, Beuthien-Baumann B, Steinbach J, Kotzerke J, et al. Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets. Nukl Nucl Med. 2012;51:9\u201316.","journal-title":"Nukl Nucl Med"},{"key":"836_CR21","unstructured":"R Core Team. R: a Language and Environment for Statistical Computing. R Found Stat Comput."},{"key":"836_CR22","doi-asserted-by":"publisher","first-page":"106948","DOI":"10.1016\/j.cmpb.2022.106948","volume":"222","author":"Y Wang","year":"2022","unstructured":"Wang Y, Lombardo E, Avanzo M, Zschaek S, Weing\u00e4rtner J, Holzgreve A, et al. Deep learning based time-to-event analysis with PET, CT and joint PET\/CT for head and neck cancer prognosis. Comput Methods Programs Biomed. 2022;222:106948.","journal-title":"Comput Methods Programs Biomed"},{"key":"836_CR23","doi-asserted-by":"publisher","first-page":"100502","DOI":"10.1016\/j.phro.2023.100502","volume":"28","author":"B Ma","year":"2023","unstructured":"Ma B, Guo J, Chu H, van Dijk LV, van Ooijen PMA, Langendijk JA, et al. Comparison of computed tomography image features extracted by radiomics, self-supervised learning and end-to-end deep learning for outcome prediction of oropharyngeal cancer. Phys Imaging Radiat Oncol. 2023;28:100502.","journal-title":"Phys Imaging Radiat Oncol"},{"key":"836_CR24","doi-asserted-by":"publisher","first-page":"e30798","DOI":"10.1097\/MD.0000000000030798","volume":"101","author":"A Jin","year":"2022","unstructured":"Jin A, Lin X, Yin X, Cui Y, Ma L. Prognostic value of MTV and TLG of 18 F-FDG PET in patients with head and neck squamous cell carcinoma: a meta-analysis. Med (Baltim). 2022;101:e30798.","journal-title":"Med (Baltim)"},{"key":"836_CR25","doi-asserted-by":"publisher","first-page":"e27427","DOI":"10.1097\/MD.0000000000027427","volume":"100","author":"H Suzuki","year":"2021","unstructured":"Suzuki H, Tamaki T, Terada H, Nishio M, Nishikawa D, Beppu S, et al. Total lesion glycolysis as a predictor of clinical T3-4a laryngeal cancer with laryngectomy or nonlaryngectomy. Med (Baltim). 2021;100:e27427.","journal-title":"Med (Baltim)"},{"key":"836_CR26","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/lary.30362","volume":"133","author":"A Noor","year":"2023","unstructured":"Noor A, Mair M, Cook L, Bolt H, Cheriyan S, Woods CM, et al. Prognostic value of 18 F-Fluoro-deoxyglucose-Positron Emission Tomography Volumetric parameters in Human Papillomavirus-related Oropharyngeal squamous cell carcinoma. Laryngoscope. 2023;133:1667\u201372.","journal-title":"Laryngoscope"},{"key":"836_CR27","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1002\/hed.25337","volume":"40","author":"JM Floberg","year":"2018","unstructured":"Floberg JM, DeWees TA, Chin R-I, Garsa AA, Dehdashti F, Nussenbaum B, et al. Pretreatment metabolic tumor volume as a prognostic factor in HPV-associated oropharyngeal cancer in the context of AJCC 8th edition staging. Head Neck. 2018;40:2280\u20137.","journal-title":"Head Neck"},{"key":"836_CR28","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/hed.25505","volume":"41","author":"T Chotchutipan","year":"2019","unstructured":"Chotchutipan T, Rosen BS, Hawkins PG, Lee JY, Saripalli AL, Thakkar D, et al. Volumetric 18 F-FDG-PET parameters as predictors of locoregional failure in low-risk HPV-related oropharyngeal cancer after definitive chemoradiation therapy. Head Neck. 2019;41:366\u201373.","journal-title":"Head Neck"}],"updated-by":[{"DOI":"10.1186\/s40644-025-00870-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000}}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00836-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-025-00836-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00836-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:05:22Z","timestamp":1744164322000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-025-00836-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1186\/s40644-025-00836-6","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s40644-025-00870-4","asserted-by":"object"}]},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"29 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40644-025-00870-4","URL":"https:\/\/doi.org\/10.1186\/s40644-025-00870-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Ethics Committee of Charit\u00e9 University Clinic Berlin. Ethics application No. EA1\/241\/22. Patients treated within prospective studies gave written informed consent to participate. For patients with retrospective evaluation of data, informed consent was waived by the committee due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of pseudonymized publication of the data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Adrien Holzgreve is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)\u2013 545058105, and reports compensation for scientific consulting by ABX advanced biochemical compounds outside the submitted work. Dr. Baumann, CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg) is responsible for collaborations with a large number of companies and institutions worldwide. In this capacity, he has signed contracts for research funding and\/or collaborations, including commercial transfers, with industry and academia on behalf of his institute(s) and staff. He is a member of several supervisory boards, advisory boards, and boards of trustees. Dr. Baumann confirms that there is no conflict of interest for this paper. Dr. Baumann confirms that, to the best of his knowledge, none of the above funding sources were involved in the preparation of this paper. Dr. Krause received funding for her research projects by IBA (2016), Merck KGaA (2014\u20132018 for preclinical study; 2018\u20132020 for clinical study), Medipan GmbH (2014\u20132018), Attomol GmbH (2019\u20132021), GA Generic Assays GmbH (2019\u20132021), BTU Cottbus-Senftenberg (2019\u20132021), Gesellschaft f\u00fcr medizinische und wissenschaftliche genetische Analysen (2019\u20132021), Lipotype GmbH (2019\u20132021), PolyAn GmbH (2019\u20132021). All other authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}